Edgar Snyder & Associates®
A Law Firm Representing Injured People
1-866-943-3427
Call Us Toll Free 24/7
Published on Oct 27, 2009 by Edgar Snyder

GAO Investigates FDA's Accelerated
Approval Program

FDA's accelerated approval program

According to the Government Accountability Office (GAO), the Food and Drug Administration (FDA) has allowed drugs to stay on the market even when follow-up studies found that they weren't effective. This and other practices are under review by the GAO, which investigated the FDA's "accelerated approval program."

The program is used to approve drugs for the most serious conditions and is intended to quickly make available medications that are anticipated to be effective. However, a condition of the program is that drug manufacturers conduct follow-up studies to confirm the drug's benefits.

A report from the GAO says that only 64 percent of the studies required under the program have been completed; one-third are pending; and in the 16 years that the FDA has used accelerated approval, it has never recalled a drug due to missing or unsatisfactory follow-up data.

The GAO concluded that the FDA has no official policy for pulling drugs off the market under the accelerated approval program. The FDA responded that it would be nearly impossible to create a standard policy for withdrawals, due to the unique circumstances of individual drugs.

Source: "GAO: FDA Doesn't Investigate Unproven Drugs." ThePittsburghChannel.com. October 26, 2009.
Think you have a case?
Think you have a case?
Free Case Review
First Name
Last Name
ZIP
Phone
Email
Briefly describe your injuries

Recent News

Sep 30, 2016
September Mocktail: Apple Pie Punch
Sep 28, 2016
Pittsburgh Police Beefing Up DUI Patrols in 2017
Sep 26, 2016
Gear Up, Cool Down, and Stay Safe While Riding This Fall
Sep 16, 2016
Fall and Winter Car Kit
Sep 16, 2016
A New Law May Be Coming for Drivers
Tweet